NZ555571A - Alpha thymosin peptides as cancer vaccine adjuvants - Google Patents

Alpha thymosin peptides as cancer vaccine adjuvants

Info

Publication number
NZ555571A
NZ555571A NZ555571A NZ55557105A NZ555571A NZ 555571 A NZ555571 A NZ 555571A NZ 555571 A NZ555571 A NZ 555571A NZ 55557105 A NZ55557105 A NZ 55557105A NZ 555571 A NZ555571 A NZ 555571A
Authority
NZ
New Zealand
Prior art keywords
cancer
vaccine
cells
subject
tumor
Prior art date
Application number
NZ555571A
Other languages
English (en)
Inventor
Gustavo Antonio Moviglia
Alfred R Rudolph
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NZ555571A publication Critical patent/NZ555571A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ555571A 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants NZ555571A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (1)

Publication Number Publication Date
NZ555571A true NZ555571A (en) 2009-02-28

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ555571A NZ555571A (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Country Status (15)

Country Link
US (1) US20100092499A1 (enExample)
EP (1) EP1835931A4 (enExample)
JP (1) JP2008523067A (enExample)
KR (1) KR20070086663A (enExample)
CN (1) CN101072582B (enExample)
AU (1) AU2005314271B2 (enExample)
BR (1) BRPI0518571A2 (enExample)
CA (1) CA2588685A1 (enExample)
EA (1) EA015510B1 (enExample)
IL (1) IL183264A (enExample)
MX (1) MX2007006717A (enExample)
NO (1) NO20072705L (enExample)
NZ (1) NZ555571A (enExample)
UA (1) UA90493C2 (enExample)
WO (1) WO2006062917A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008338594A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
EP2804626B1 (en) 2012-01-20 2019-05-01 Fernando Thome Kreutz Autologous cancer cell vaccine
WO2013134666A1 (en) * 2012-03-08 2013-09-12 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
EP3943101A1 (en) * 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
NZ516381A (en) * 1999-06-30 2004-03-26 Corixa Corp Lung tumor proteins in the therapy and diagnosis of lung cancer
MXPA04003867A (es) * 2001-10-26 2005-06-17 Rhode Island Hospital Uso de la timosina para aumentar la inmunizacion genetica y composiciones farmaceuticas inmunologicas a base de timosina.
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
US20060052297A1 (en) 2002-06-28 2006-03-09 Guido Rasi Method of up-regulating tumor antigen expression using thymalfasin
DK1613340T3 (da) * 2003-03-28 2010-08-30 Sciclone Pharmaceuticals Inc Behandling af aspergillus-infektioner med thymosin alfa 1
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas

Also Published As

Publication number Publication date
AU2005314271A1 (en) 2006-06-15
EP1835931A4 (en) 2008-12-17
EA200701166A1 (ru) 2008-02-28
CN101072582B (zh) 2012-06-27
US20100092499A1 (en) 2010-04-15
NO20072705L (no) 2007-09-05
MX2007006717A (es) 2007-08-06
EP1835931A2 (en) 2007-09-26
KR20070086663A (ko) 2007-08-27
CN101072582A (zh) 2007-11-14
CA2588685A1 (en) 2006-06-15
WO2006062917A2 (en) 2006-06-15
IL183264A0 (en) 2007-09-20
EA015510B1 (ru) 2011-08-30
UA90493C2 (ru) 2010-05-11
AU2005314271B2 (en) 2011-06-16
BRPI0518571A2 (pt) 2008-11-25
IL183264A (en) 2010-12-30
JP2008523067A (ja) 2008-07-03
WO2006062917A3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
EP1001806B1 (fr) Vesicule cellulaire denommee 'exosome', preparation et utilisation dans la stimulation d'une reponse immunitaire
EP2787005A1 (en) Targeted cancer immune therapy
US20100303868A1 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
Fujii et al. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
NZ555571A (en) Alpha thymosin peptides as cancer vaccine adjuvants
Fu et al. Therapeutic antitumor efficacy of cancer stem cell-derived dribble vaccine on colorectal carcinoma
Banchereau Dendritic cells: therapeutic potentials
RU2192274C2 (ru) Иммуногенная композиция на основе tlp
ZA200703528B (en) Immunotherapeutic formulations with Interleukin-2-neutralising capacity
JP2002502880A (ja) ハプテン改変化腫瘍細胞膜およびその使用
CN111298111A (zh) 一种治疗和/或预防癌症的药物和应用
US20090060946A1 (en) Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
Das et al. Immunotherapeutic treatment strategies for primary brain tumors
WO2023215825A1 (en) Methods for improving t cell efficacy
WO2004096244A1 (en) Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
Dadwal et al. From past to present: The evolution of immunotherapy and its modern modalities
Huete-Carrasco et al. Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T cell responses and anti-tumour immunity by targeting conventional type 1 dendritic cells.
HK1113374B (en) Immunotherapeutic formulations with interleukin-2-neutralising capacity

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SCICLONE PHARMACEUTICALS, US

Free format text: OLD OWNER(S): SCICLONE PHARMACEUTICALS, INC.

ASS Change of ownership

Owner name: SCICLONE PHARMACEUTICALS, US

Free format text: OLD OWNER(S): SCICLONE PHARMACEUTICALS, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed